Golimumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Golimumab: From Inflammatory Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Golimumab is a fully human anti-TNF-α monoclonal antibody (marketed as Simponi), originally used for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, but the current evidence base is limited to 3 clinical trials (none golimumab-specific for this indication) and 6 publications, mostly case reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (per literature evidence, e.g. PMID 28530020, 20065639) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not directly available in this evidence pack (original_moa: [Data Gap]). Based on information found within the collected literature, golimumab is a fully human anti-TNF-α IgG1κ monoclonal antibody, approved in the EU for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis) (PMID 20065639, 28530020).
Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis, driven by the same TNF-α-mediated inflammatory pathways that golimumab already targets. One case report in this evidence pack (PMID 29075910) explicitly notes that “the introduction of biologic disease-modifying drugs, such as anti-TNFα agents, has attenuated the incidence of rheumatoid vasculitis.” This provides a plausible mechanistic rationale for the TxGNN prediction.
However, the supporting evidence is mixed and largely indirect. On one hand, golimumab has been used successfully off-label for other vasculitic/inflammatory conditions, e.g. Behçet’s disease-associated uveitis (PMID 23252659). On the other hand, a separate case report describes Takayasu’s arteritis (a large-vessel vasculitis) occurring under anti-TNF therapy (PMID 22999907), suggesting the drug class’s effect on vasculitis is not uniformly protective. No trial or publication in this pack directly evaluates golimumab as a treatment for rheumatoid vasculitis specifically — the connection remains mechanistic and anecdotal rather than proven.
Clinical Trial Evidence
None of the 3 retrieved trials directly test golimumab for rheumatoid vasculitis; they are broader RA/immune-mediated disease registries returned by the search.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01579006 | N/A | Completed | 184 | Observational study of tocilizumab (Actemra, not golimumab) in RA patients with inadequate response to non-biological DMARDs — not golimumab-specific |
| NCT05696106 | N/A | Unknown | 750,000 | Large epidemiological study on the risk of developing a second immune-mediated inflammatory disease (IMID) in patients already treated with biologics/immunosuppressants for one IMID |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Assesses rheumatologic flare/complication rates when holding immunosuppressants (general, not golimumab- or vasculitis-specific) perioperatively for shoulder arthroplasty |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29075910 | 2018 | Case report | Rheumatology International | Golimumab-treated RA patient developed pyoderma gangrenosum/pyogenic arthritis presenting as severe sepsis; notes anti-TNF agents have reduced rheumatoid vasculitis incidence |
| 31491879 | 2019 | Network meta-analysis (36 RCTs) | Int J Mol Sci | Original and biosimilar TNF inhibitors (incl. golimumab) similarly reduce joint destruction in RA vs. methotrexate; not vasculitis-specific |
| 27591827 | 2017 | Review | Semin Arthritis Rheum | Frequency, causes and RA treatment considerations in end-stage renal disease; general RA context |
| 23557513 | 2013 | Review | BMC Medicine | Update on biologic therapy for autoimmune diseases generally |
| 22999907 | 2013 | Case report | Joint Bone Spine | Two cases of Takayasu’s arteritis (large-vessel vasculitis) occurring under anti-TNF therapy — cautionary signal |
| 23252659 | 2013 | Case report | Ocular Immunol Inflamm | Behçet disease-associated uveitis successfully treated with golimumab, supporting off-label anti-inflammatory/vasculitic use |
Safety Considerations
Please refer to the SmPC for safety information. (No warnings, contraindications, or drug interaction data were available in this evidence pack — DDI query returned not_found.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for golimumab in rheumatoid vasculitis is indirect and case-report level (L4) rather than trial-confirmed, with one case report even describing vasculitis onset under anti-TNF therapy — a mixed safety signal. The drug also has no current EU marketing authorization on file in this dataset, and critical safety data (warnings, contraindications) is entirely missing, which blocks a S1 safety evaluation.
To proceed, the following is needed:
- TFDA/EMA product label (SmPC) with warnings and contraindications (blocking gap, per data gap DG001)
- Confirmed mechanism of action data via DrugBank API (data gap DG002)
- Targeted literature/trial search specifically for golimumab (or class-level anti-TNF) efficacy and safety in rheumatoid vasculitis, rather than general RA/IMID studies
- Clarification of the conflicting signal between anti-TNF therapy attenuating vs. potentially triggering vasculitis in select case reports
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.